Sackeim et al 200810
|
22 |
55.0% |
54.0 |
16.0 |
22.0 |
8.0 |
not stated; 1 pt at 4.8 mC, rest at 19.2 or 38.4 mC |
Sienaert et al 200919
|
32 |
71.9% |
54.4 |
13.1 |
38.4 |
24.9 |
starting at 24 mC |
McCormick et al 200920
|
26 |
73.0% |
53.2 |
14.5 |
51.4 |
108.7 |
not stated |
Roepke et al 201121
|
17 |
55.0% |
54.3 |
15.5 |
37.5 |
12.1 |
not stated; group 1 of trial |
Roepke et al 201121
|
17 |
65.0% |
57.9 |
14.3 |
40.6 |
26.2 |
not stated; group 2 of trial |
Quante et al 201122
|
41 |
76.8% |
56.4 |
13.9 |
13.9 |
15.1 |
MECTA starting at 9.2 mC |
van Waarde et al 201223
|
63 |
62.6% |
59.1 |
15.0 |
45.6 |
16.8 |
Thymatron starting at 25.2 mC for pt < 50; 50.4 mC for patients >50 |
Rosa et al 201324
|
30 |
60.0% |
52.0 |
15.2 |
36.1 |
15.1 |
MECTA table starting at 9.6 mC |
Spaans et al 201325
|
58 |
70.7% |
60.4 |
16.3 |
23.9 |
10.2 |
MECTA table starting at 9.6 mC |
Mayur et al 201326
|
17 |
52.9% |
43.4 |
11.7 |
22.1 |
8.9 |
MECTA table starting at 9.6 mC |
Galvez et al 201511
|
179 |
60.9% |
45.7 |
14.7 |
31.7 |
22.2 |
MECTA table starting at 9.6 mC or Thymatron 10 mC |
Kellner et al 201613
|
240 |
57.5% |
69.9 |
7.6 |
30.5 |
14.3 |
MECTA starting at 24 mC or Thymatron starting at 5% (25 mC) |
Rasmussen at al 201627
|
20 |
80.0% |
47.7 |
12.9 |
32.7 |
17.8 |
Thymatron starting at 5% (25 mC) |
Galvez et al 201728
|
35 |
51.4% |
50.2 |
15.6 |
27.7 |
11.5 |
MECTA table starting at 9.6 mC or Thymatron 10 mC |
Wong et al 201929
|
13 |
23.1% |
20.3 |
12.6 |
39.2 |
28.8 |
Thymatron, titration not stated |